Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LX 2020

Next Previous
Drug Profile

LX 2020

Alternative Names: AAV-PKP2; ARVC PKP2 - LEXEO Therapeutics; LX-2020

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stelios Therapeutics
  • Developer LEXEO Therapeutics
  • Class Cardiovascular therapies; Gene therapies
  • Mechanism of Action Gene transference; Plakophilin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Arrhythmogenic right ventricular dysplasia

Most Recent Events

  • 12 Jan 2026 Lexeo Therapeutics plans regulatory engagements in 2026
  • 12 Jan 2026 Efficacy, pharmacodynamics and adverse events data from a phase I/II HEROIC-PKP2 trial in Arrhythmogenic right ventricular dysplasia released by LEXEO Therapeutics
  • 31 Dec 2025 Lexeo Therapeutics completes enrolment in a phase I/II HEROIC-PKP2 trial for Arrhythmogenic right ventricular dysplasia (In adults) in USA (IV) (NCT06109181)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top